Antibiotic LL-E19020 Alpha.sub.1

• US 5,814,615 A
• Filed: 09/09/1991
• Issued: 09/29/1998
• Est. Priority Date: 09/09/1991
• Status: Expired due to Fees

• Current Assignee: Roche Vitamins, Inc. (Roche Holding AG)
• Original Assignee: Roche Vitamins, Inc. (Roche Holding AG)
• Inventors: Williams, David R., Carter, Guy Thomas, Korshalla, Joseph D.
• Primary Examiner(s): Kunz, Gary L.
• Application Number:
  US07/756,646
• Time in Patent Office: 2,577 Days
• Field of Search: 536/16.8, 536/18.1, 536/18.7, 536/25, 514/25.23, 424/122
• US Class Current: 514/25
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: C07H 15/26 Acyclic or carbocyclic radicals, substituted by hetero rings
• CPC Class Codes: C07H 7/02 Acyclic radicals
• CPC Class Codes: C12P 19/44 Preparation of O-glycosides, e.g. glucosides polysaccharides and not substituted disaccharides C12P19/04, C12P19/12

Abstract

The invention provides an antibiotic designated LL-E19020 Alpha₁ which is derived from the micro-organism Streptomyces lydicus ssp. tanzanius NRRL 18036.

Claims

1. A compound LL-E19020 Alpha₁ comprising

(a) the structure ##STR4## (b) a molecular weight of 1225 (FABMS=M/Z 1248 corresponding to M+Na!+);

(c) a molecular formula;

C₆₅ H₉₅ NO₂₁

(d) a characteristic ultraviolet absorption spectra as shown in FIG. I of the attached drawings;

(e) a characteristic infrared absorption spectrum as shown in FIG. II of the attached drawings;

(f) a characteristic proton nuclear magnetic resonance spectrum as shown in FIG. III of the attached drawings; and

(g) a characteristic carbon-13 nuclear magnetic resonance spectrum as shown in FIG. IV of the attached drawings.

(h) a characteristic HPLC retention time of 23.1 minutes using a gradient of dioxane in aqueous acetic acid.

2. A method of treating bacterial infections in warm blooded animals which comprises administering to said animals an antibacterially effective amount of antibiotic LL-E19020 Alpha₁ as defined in claim 1.

3. A antibiotic pharmaceutical composition which comprises an antibiotic amount of LL-E19020 Alpha₁ as defined in claim 1 in association with a pharmaceutically acceptable carrier.